Yoon-Sim Yap
Overview
Explore the profile of Yoon-Sim Yap including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1972
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan R, Ong W, Lee K, Park S, Iqbal J, Park Y, et al.
J Natl Compr Canc Netw
. 2024 May;
22(2 D).
PMID: 38744306
Background: Although considered a favorable subtype, pure mucinous breast cancer (PMBC) can recur, and evidence for adjuvant therapy is limited. We aimed to compare outcomes of nonmetastatic PMBC with invasive...
2.
Prat A, Solovieff N, Andre F, OShaughnessy J, Cameron D, Janni W, et al.
Clin Cancer Res
. 2023 Nov;
30(4):793-802.
PMID: 37939142
Purpose: The MONALEESA-2, -3, -7 trials demonstrated statistically significant and clinically meaningful progression-free survival and overall survival (OS) benefits with ribociclib plus endocrine therapy (ET) versus ET alone in hormone...
3.
Loh J, Lim A, Chan J, Yap Y
Ther Adv Med Oncol
. 2023 Nov;
15:17588359231206259.
PMID: 37920257
Background: Recently, HER2-negative breast cancers have been reclassified by protein expression into 'HER2-low' and 'HER2-zero' subgroups, but the consideration of HER2-low breast cancer as a distinct biological subtype with differing...
4.
Ma J, Chan J, Toh C, Yap Y
NPJ Breast Cancer
. 2023 Sep;
9(1):74.
PMID: 37684290
Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the standard first-line treatment for most patients with hormone receptor (HR) positive, human epidermal growth factor receptor (HER2) negative...
5.
Chiu J, Su F, Joshi M, Masuda N, Ishikawa T, Aruga T, et al.
BMC Med
. 2023 Aug;
21(1):306.
PMID: 37580773
Background: There is increasing interest in the use of liquid biopsies, but data on longitudinal analyses of circulating tumor DNA (ctDNA) remain relatively limited. Here, we report a longitudinal ctDNA...
6.
Lee N, Hum M, Zihara S, Wang L, Myint M, Lim D, et al.
Hum Genomics
. 2023 Aug;
17(1):74.
PMID: 37580755
No abstract available.
7.
Lee N, Hum M, Zihara S, Wang L, Myint M, Lim D, et al.
Hum Genomics
. 2023 Jul;
17(1):66.
PMID: 37461096
Background: Cancer predisposition is most often studied in the context of single cancers. However, inherited cancer predispositions can also give rise to multiple primary cancers. Yet, there is a paucity...
8.
Yap Y, Hu J
Cell Rep Med
. 2023 Apr;
4(4):101010.
PMID: 37075699
Auf der Maur et al. identify neurofibromin 1 (NF1) loss as a mechanism of resistance to PI3K inhibitor in breast cancer cells. NF1 loss leads to enhanced glycolysis, which may...
9.
Ithimakin S, Parinyanitikul N, Kim S, Yap Y, Tsang J, Soong I, et al.
J Breast Cancer
. 2022 Jun;
25(3):207-217.
PMID: 35657002
Purpose: Breast cancer (BC) treatment has shifted from chemotherapy to targeted therapy. Several targeted agents have demonstrated an improvement in survival. Given that national healthcare resources were correlated with the...
10.
Wan J, Mughal T, Razavi P, Dawson S, Moss E, Govindan R, et al.
Med
. 2022 May;
2(12):1292-1313.
PMID: 35590147
Detection of minimal residual disease in patients with cancer, who are in complete remission with no cancer cells detectable, has the potential to improve recurrence-free survival through treatment selection. Studies...